The Conversation (0)
Chart
Detailed Quote
CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drug such as CB4209 and CB4211, SHLP-6, SHLP-2 and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operation of the group is functioned through the region of United States.
Featured Articles and Interviews
Press Releases
May 03, 2019
CohBar to Resume its Phase 1a/1b Clinical Trial
See More Press Releases
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.